Rocket Pharmaceuticals(US:RCKT) Prnewswireยท2025-07-03 11:50Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced legal scrutiny following a clinical hold placed by the FDA on its RP-A501 Phase 2 pivotal study due to serious adverse events, including a participant's death [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. Group 3: Financial Impact - Following the announcement of the FDA's clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].